TY  - JOUR
AU  - Pineda, J. A.
AU  - Morano-Amado, L. E.
AU  - Granados, R.
AU  - Macias, J.
AU  - Tellez, F.
AU  - Garcia-Deltoro, M.
AU  - Rios, M. J.
AU  - Collado, A.
AU  - Delgado-Fernandez, M.
AU  - Suarez-Santamaria, M.
AU  - Serrano, M.
AU  - Miralles-Alvarez, C.
AU  - Neukam, K.
AU  - Sociedad Espanola Enfermedades
AU  - Sociedad Andaluza Enfermedades
PY  - 2017
DO  - 10.1016/j.cmi.2016.12.034
SN  - 1198-743X
UR  - http://hdl.handle.net/10668/18752
T2  - Clinical microbiology and infection
AB  - Objective: The aim of this study was to determine the predictive capacity of response at treatment week (TW) 4 for the achievement of sustained virological response 12 weeks after the scheduled end of therapy date (SVR12) to treatment against...
LA  - en
PB  - Elsevier sci ltd
KW  - Cirrhosis
KW  - Direct-acting antivirals
KW  - Hepatitis C virus genotype 3
KW  - Interferon-free regimens
KW  - Sustained virological response
KW  - Viral kinetics
KW  - Phase-iii
KW  - Sofosbuvir
KW  - Hcv
KW  - Velpatasvir
KW  - Daclatasvir
KW  - Ribavirin
TI  - Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
TY  - research article
VL  - 23
ER  -